Prevalence of pilomatricoma in turner syndrome findings from a multicenter study

Marc Z. Handler, Kristina M. Derrick, Richard E Lutz, Dean S. Morrell, Marsha L. Davenport, April W. Armstrong

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Importance: The absence of data on the prevalence of pilomatricoma among patients with Turner syndrome served as the catalyst for this multicenter investigation. Objectives: To ascertain the prevalence of pilomatricoma among patients with Turner syndrome and to determine any association between the development of pilomatricomas and the use of exogenous hormones in patients with Turner syndrome. Design: A retrospective medical record review from January 1, 2000, through January 1, 2010, was performed of all patients with Turner syndrome. Data on pilomatricomas and the use of hormone therapy were collected. Setting: University of California-Davis Medical Center, University of Nebraska Medical Center, and The University of North Carolina at Chapel Hill. Participants: Patients with a diagnosis of Turner syndrome. Main Outcome Measures: Prevalence of concomitant pilomatricoma and diagnosis of Turner syndrome. Secondary outcome measures included the use of the exogenous hormones estrogen or recombinant human growth hormone (rhGH). Results: In total, 311 patients with Turner syndrome were identified from these 3 institutions. Among them, 8 patients (2.6%) were diagnosed as having pilomatricomas. Before the development of pilomatricomas, 5 patients had been treated with rhGH but not estrogen, 1 patient had received estrogen but not rhGH, and 2 patients did not receive either therapy. Conclusions and Relevance: Although the prevalence of pilomatricoma among the general population is unknown, this study demonstrates a high prevalence (2.6%) of pilomatricomas among patients with Turner syndrome. No apparent relationship was noted among our patients or in the literature between the use of rhGH and the development of pilomatricomas.

Original languageEnglish (US)
Pages (from-to)559-564
Number of pages6
JournalJAMA Dermatology
Volume149
Issue number5
DOIs
StatePublished - May 1 2013

Fingerprint

Pilomatrixoma
Turner Syndrome
Multicenter Studies
Human Growth Hormone
Growth Hormone
Estrogens
Hormones
Outcome Assessment (Health Care)
Growth and Development
Medical Records

ASJC Scopus subject areas

  • Dermatology

Cite this

Handler, M. Z., Derrick, K. M., Lutz, R. E., Morrell, D. S., Davenport, M. L., & Armstrong, A. W. (2013). Prevalence of pilomatricoma in turner syndrome findings from a multicenter study. JAMA Dermatology, 149(5), 559-564. https://doi.org/10.1001/2013.jamadermatol.115

Prevalence of pilomatricoma in turner syndrome findings from a multicenter study. / Handler, Marc Z.; Derrick, Kristina M.; Lutz, Richard E; Morrell, Dean S.; Davenport, Marsha L.; Armstrong, April W.

In: JAMA Dermatology, Vol. 149, No. 5, 01.05.2013, p. 559-564.

Research output: Contribution to journalArticle

Handler, MZ, Derrick, KM, Lutz, RE, Morrell, DS, Davenport, ML & Armstrong, AW 2013, 'Prevalence of pilomatricoma in turner syndrome findings from a multicenter study', JAMA Dermatology, vol. 149, no. 5, pp. 559-564. https://doi.org/10.1001/2013.jamadermatol.115
Handler, Marc Z. ; Derrick, Kristina M. ; Lutz, Richard E ; Morrell, Dean S. ; Davenport, Marsha L. ; Armstrong, April W. / Prevalence of pilomatricoma in turner syndrome findings from a multicenter study. In: JAMA Dermatology. 2013 ; Vol. 149, No. 5. pp. 559-564.
@article{bc6dfcd47da148edb12f542c4ce04fe4,
title = "Prevalence of pilomatricoma in turner syndrome findings from a multicenter study",
abstract = "Importance: The absence of data on the prevalence of pilomatricoma among patients with Turner syndrome served as the catalyst for this multicenter investigation. Objectives: To ascertain the prevalence of pilomatricoma among patients with Turner syndrome and to determine any association between the development of pilomatricomas and the use of exogenous hormones in patients with Turner syndrome. Design: A retrospective medical record review from January 1, 2000, through January 1, 2010, was performed of all patients with Turner syndrome. Data on pilomatricomas and the use of hormone therapy were collected. Setting: University of California-Davis Medical Center, University of Nebraska Medical Center, and The University of North Carolina at Chapel Hill. Participants: Patients with a diagnosis of Turner syndrome. Main Outcome Measures: Prevalence of concomitant pilomatricoma and diagnosis of Turner syndrome. Secondary outcome measures included the use of the exogenous hormones estrogen or recombinant human growth hormone (rhGH). Results: In total, 311 patients with Turner syndrome were identified from these 3 institutions. Among them, 8 patients (2.6{\%}) were diagnosed as having pilomatricomas. Before the development of pilomatricomas, 5 patients had been treated with rhGH but not estrogen, 1 patient had received estrogen but not rhGH, and 2 patients did not receive either therapy. Conclusions and Relevance: Although the prevalence of pilomatricoma among the general population is unknown, this study demonstrates a high prevalence (2.6{\%}) of pilomatricomas among patients with Turner syndrome. No apparent relationship was noted among our patients or in the literature between the use of rhGH and the development of pilomatricomas.",
author = "Handler, {Marc Z.} and Derrick, {Kristina M.} and Lutz, {Richard E} and Morrell, {Dean S.} and Davenport, {Marsha L.} and Armstrong, {April W.}",
year = "2013",
month = "5",
day = "1",
doi = "10.1001/2013.jamadermatol.115",
language = "English (US)",
volume = "149",
pages = "559--564",
journal = "JAMA Dermatology",
issn = "2168-6068",
publisher = "American Medical Association",
number = "5",

}

TY - JOUR

T1 - Prevalence of pilomatricoma in turner syndrome findings from a multicenter study

AU - Handler, Marc Z.

AU - Derrick, Kristina M.

AU - Lutz, Richard E

AU - Morrell, Dean S.

AU - Davenport, Marsha L.

AU - Armstrong, April W.

PY - 2013/5/1

Y1 - 2013/5/1

N2 - Importance: The absence of data on the prevalence of pilomatricoma among patients with Turner syndrome served as the catalyst for this multicenter investigation. Objectives: To ascertain the prevalence of pilomatricoma among patients with Turner syndrome and to determine any association between the development of pilomatricomas and the use of exogenous hormones in patients with Turner syndrome. Design: A retrospective medical record review from January 1, 2000, through January 1, 2010, was performed of all patients with Turner syndrome. Data on pilomatricomas and the use of hormone therapy were collected. Setting: University of California-Davis Medical Center, University of Nebraska Medical Center, and The University of North Carolina at Chapel Hill. Participants: Patients with a diagnosis of Turner syndrome. Main Outcome Measures: Prevalence of concomitant pilomatricoma and diagnosis of Turner syndrome. Secondary outcome measures included the use of the exogenous hormones estrogen or recombinant human growth hormone (rhGH). Results: In total, 311 patients with Turner syndrome were identified from these 3 institutions. Among them, 8 patients (2.6%) were diagnosed as having pilomatricomas. Before the development of pilomatricomas, 5 patients had been treated with rhGH but not estrogen, 1 patient had received estrogen but not rhGH, and 2 patients did not receive either therapy. Conclusions and Relevance: Although the prevalence of pilomatricoma among the general population is unknown, this study demonstrates a high prevalence (2.6%) of pilomatricomas among patients with Turner syndrome. No apparent relationship was noted among our patients or in the literature between the use of rhGH and the development of pilomatricomas.

AB - Importance: The absence of data on the prevalence of pilomatricoma among patients with Turner syndrome served as the catalyst for this multicenter investigation. Objectives: To ascertain the prevalence of pilomatricoma among patients with Turner syndrome and to determine any association between the development of pilomatricomas and the use of exogenous hormones in patients with Turner syndrome. Design: A retrospective medical record review from January 1, 2000, through January 1, 2010, was performed of all patients with Turner syndrome. Data on pilomatricomas and the use of hormone therapy were collected. Setting: University of California-Davis Medical Center, University of Nebraska Medical Center, and The University of North Carolina at Chapel Hill. Participants: Patients with a diagnosis of Turner syndrome. Main Outcome Measures: Prevalence of concomitant pilomatricoma and diagnosis of Turner syndrome. Secondary outcome measures included the use of the exogenous hormones estrogen or recombinant human growth hormone (rhGH). Results: In total, 311 patients with Turner syndrome were identified from these 3 institutions. Among them, 8 patients (2.6%) were diagnosed as having pilomatricomas. Before the development of pilomatricomas, 5 patients had been treated with rhGH but not estrogen, 1 patient had received estrogen but not rhGH, and 2 patients did not receive either therapy. Conclusions and Relevance: Although the prevalence of pilomatricoma among the general population is unknown, this study demonstrates a high prevalence (2.6%) of pilomatricomas among patients with Turner syndrome. No apparent relationship was noted among our patients or in the literature between the use of rhGH and the development of pilomatricomas.

UR - http://www.scopus.com/inward/record.url?scp=84877854054&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877854054&partnerID=8YFLogxK

U2 - 10.1001/2013.jamadermatol.115

DO - 10.1001/2013.jamadermatol.115

M3 - Article

C2 - 23426075

AN - SCOPUS:84877854054

VL - 149

SP - 559

EP - 564

JO - JAMA Dermatology

JF - JAMA Dermatology

SN - 2168-6068

IS - 5

ER -